Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating Expenses:
Research and development	$ 3,162	$ 3,234	$ 6,341	$ 6,516
General and administrative	3,713	3,486	7,378	6,824
Total operating expenses	6,875	6,720	13,719	13,340
Operating loss	(6,875)	(6,720)	(13,719)	(13,340)
Other income (expense):
Investment income, net	668	94	1,338	158
Other expense, net	(150)	0	(163)	(149)
Total other income (expense)	518	94	1,175	9
Net loss before benefit from income taxes and noncontrolling interests	(6,357)	(6,626)	(12,544)	(13,331)
Benefit from income taxes	(2,330)	0	(2,330)	(2,479)
Net loss	(4,027)	(6,626)	(10,214)	(10,852)
Less - net income attributable to noncontrolling interests	0	0	0	0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders	$ (4,027)	$ (6,626)	$ (10,214)	$ (10,852)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)	$ (0.50)	$ (1.64)	$ (1.28)	$ (2.69)
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)	$ (0.50)	$ (1.64)	$ (1.28)	$ (2.69)
Weighted average common shares outstanding
Basic shares	8,021	4,035	8,004	4,036
Diluted shares	8,021	4,035	8,004	4,036